This is an open label randomized trial to evaluate the efficacy and treatment duration with
vedolizumab to patients with immune mediated colitis. The trial will include 82 patients
randomized into two arms, either standard treatment with prednisolone (plus infliximab in
severe cases) or vedolizumab treatment up front.